Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

EC approves Pfizer's CCR5 antagonist and oral entry inhibitor Celsentri

Sep. 25, 2007

Merck and HVTN discontinue clinical trials of HIV vaccine V-520

Sep. 25, 2007

TMC-125 NDA accepted for priority review in U.S.

Sep. 21, 2007

RDEA-806: a novel anti-HIV NNRTI safe and well tolerated in human studies

Sep. 21, 2007

Schering-Plough begins two phase III studies of CCR5 antagonist vicriviroc

Sep. 19, 2007

Novel chemokine CCR5 receptor antagonists emerge from Roche R&D

Sep. 12, 2007

Accelerated approval of Merck & Co.'s Isentress recommended by FDA Advisory Committee

Sep. 7, 2007

Patient recruitment complete for tesamorelin confirmatory phase III trial

Sep. 7, 2007

Boehringer Ingelheim offers Apotex nevirapine license in developing countries

Sep. 5, 2007

Positive interim results from Avexa's phase IIb trial of apricitabine for HIV

Sep. 4, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...